NICE reconsiders and agrees to back Roche’s Ocrevus in relapsing multiple sclerosis—with strings attached

22nd June 2018 Uncategorised 0

About two months after England’s cost watchdog decided Roche’s multiple sclerosis star Ocrevus wasn’t cost-effective enough to win reimbursement backing in relapsing forms of the disease, the agency overturned that ruling with one limitation.

More: NICE reconsiders and agrees to back Roche’s Ocrevus in relapsing multiple sclerosis—with strings attached
Source: fierce